# Interstitial lung changes and persistent COVID‐19 in a patient with follicular lymphoma: A case report

## TL;DR

A patient with follicular lymphoma experienced long-term lung changes from COVID-19 and recovered after corticosteroid and immunosuppressive treatment.

## Contribution

This case report presents a novel treatment approach for persistent interstitial lung changes in immunocompromised patients with prolonged COVID-19.

## Key findings

- Interstitial lung changes persisted for over 11 months in a patient with follicular lymphoma.
- Corticosteroids alone were ineffective, but combination therapy with immunosuppressive agents led to recovery.
- Persistent pneumonitis after COVID-19 is a life-threatening condition in immunocompromised individuals.

## Abstract

We herein report a case of interstitial lung changes in a patient with prolonged coronavirus disease 2019 (COVID‐19) with follicular lymphoma receiving rituximab and bendamustine who recovered after treatment with a combination therapy consisting of corticosteroids and immunosuppressive agents. There is currently no treatment strategy for prolonged pneumonitis following COVID‐19, which can be life‐threatening for immunocompromised patients. Thus, further investigation is warranted.

Herein, we report a case of COVID‐19 persisting longer than 11 months which developed interstitial changes in the lungs that were recalcitrant to corticosteroid therapy.